Trial intelligence / Profile preview

Neratinib + paclitaxel vs trastuzumab + paclitaxel in HER2-positive locally recurrent or metastatic breast cancer

CTR20181278Phase 3Completed

Sponsor

Puma Biotechnology, Inc.

Start

May 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1